Evidence map›Paper›PMID 42781491›Full record

ArticleiScience2026

Chimeric SARS-CoV-2 vaccine vectors stably incorporating the functional glycoprotein of VSV.

Enja Tatjana Kipfer, Jacob Schön, Mohamed Chami, Stefan Finke, Martin Beer, Donata Hoffmann, Fabian Otte, David Hauser

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Enja Tatjana KipferMolecular Virology, Department of Biomedicine, University of Basel, 4009 Basel, Switzerland.
Jacob SchönInstitute of Diagnostic Virology, Friedrich-Loeffler-Institut, 17493 Greifswald-Riems, Germany.
Mohamed ChamiBioEM Lab, Biozentrum, University of Basel, 4058 Basel, Switzerland.
Stefan FinkeInstitute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, 17493 Greifswald-Riems, Germany.
Martin BeerInstitute of Diagnostic Virology, Friedrich-Loeffler-Institut, 17493 Greifswald-Riems, Germany.
Donata HoffmannInstitute of Diagnostic Virology, Friedrich-Loeffler-Institut, 17493 Greifswald-Riems, Germany.
Fabian OtteMolecular Virology, Department of Biomedicine, University of Basel, 4009 Basel, Switzerland.
David HauserMolecular Virology, Department of Biomedicine, University of Basel, 4009 Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory viruses, such as SARS-CoV-2, remain a global medical challenge, highlighting the need for adaptable vaccine platforms that elicit broad immunity while allowing flexible antigen design. Building on our established envelope-deleted (ΔE) SARS-CoV-2 vaccine candidate, we engineered chimeric variants that stably express the glycoprotein of vesicular stomatitis virus (VSV-G) as a model antigen, with or without co-expression of the native SARS-CoV-2 spike protein. Both constructs were genetically stable and displayed functional VSV-G, as shown by expanded, ACE2-independent tropism. Cryo-electron microscopy confirmed the presence of heterologous glycoproteins on virions.

Indexed as

bivalent viral vectorchimericdual-immunogenicityglycoproteinpseudotypingSARS-CoV-2vaccine platformVSV-G

Identifiers

PMID42781491
PMCPMC13599654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.